BiotechTube

Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Conditions

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

Trial Timeline

Oct 6, 2021 → Jan 18, 2031

NCT ID
NCT04971226

About Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib

Imatinib + Nilotinib + Bosutinib + Dasatinib + Asciminib is a phase 3 stage product being developed by Novartis for Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive. The current trial status is active. This product is registered under clinical trial identifier NCT04971226. Target conditions include Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04971226Phase 3Active

Competing Products

20 competing products in Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25